Mohammed Moursi
Concepts (301)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endarterectomy, Carotid | 13 | 2017 | 62 | 2.960 |
Why?
| Tunica Intima | 11 | 2011 | 55 | 2.720 |
Why?
| Vascular Surgical Procedures | 7 | 2018 | 168 | 2.020 |
Why?
| Homocysteine | 8 | 2011 | 128 | 1.510 |
Why?
| Carotid Stenosis | 5 | 2017 | 63 | 1.400 |
Why?
| Carotid Arteries | 5 | 2010 | 85 | 1.210 |
Why?
| Endovascular Procedures | 7 | 2019 | 169 | 1.150 |
Why?
| Vascular Diseases | 2 | 2018 | 74 | 1.140 |
Why?
| Aortic Aneurysm, Abdominal | 5 | 2019 | 51 | 1.120 |
Why?
| Carotid Artery, Common | 4 | 2011 | 44 | 1.000 |
Why?
| Platelet Aggregation Inhibitors | 4 | 2006 | 174 | 0.870 |
Why?
| Hyperplasia | 11 | 2011 | 99 | 0.830 |
Why?
| Arterial Occlusive Diseases | 9 | 2017 | 81 | 0.760 |
Why?
| Certification | 1 | 2018 | 49 | 0.620 |
Why?
| Blood Vessel Prosthesis Implantation | 5 | 2019 | 119 | 0.600 |
Why?
| Rats, Sprague-Dawley | 12 | 2011 | 1595 | 0.580 |
Why?
| Risk Reduction Behavior | 1 | 2017 | 59 | 0.580 |
Why?
| Rats | 14 | 2011 | 3300 | 0.570 |
Why?
| Pediatrics | 1 | 2018 | 277 | 0.510 |
Why?
| Insulin Resistance | 2 | 2010 | 264 | 0.500 |
Why?
| Tobacco Use Disorder | 1 | 2017 | 168 | 0.500 |
Why?
| Time Factors | 15 | 2019 | 2912 | 0.500 |
Why?
| Ticlopidine | 2 | 2006 | 55 | 0.500 |
Why?
| Iliac Aneurysm | 1 | 2014 | 10 | 0.490 |
Why?
| Salivary Proteins and Peptides | 2 | 2004 | 8 | 0.480 |
Why?
| Receptors, N-Methyl-D-Aspartate | 2 | 2005 | 126 | 0.480 |
Why?
| Smoking | 2 | 2017 | 510 | 0.470 |
Why?
| Pelvis | 1 | 2014 | 68 | 0.470 |
Why?
| Hemostatic Techniques | 5 | 2017 | 28 | 0.470 |
Why?
| Smoking Cessation | 1 | 2017 | 299 | 0.470 |
Why?
| Patient Acceptance of Health Care | 1 | 2017 | 327 | 0.460 |
Why?
| Muscle, Smooth, Vascular | 3 | 2005 | 131 | 0.440 |
Why?
| Male | 34 | 2019 | 25093 | 0.430 |
Why?
| Disease Models, Animal | 7 | 2011 | 1451 | 0.430 |
Why?
| Internship and Residency | 1 | 2018 | 446 | 0.420 |
Why?
| Carotid Artery Injuries | 1 | 2011 | 13 | 0.400 |
Why?
| Femoral Artery | 5 | 2016 | 100 | 0.370 |
Why?
| Acarbose | 1 | 2010 | 2 | 0.370 |
Why?
| Estradiol | 1 | 2011 | 225 | 0.360 |
Why?
| Animals | 17 | 2011 | 13150 | 0.350 |
Why?
| Blood Vessel Prosthesis | 5 | 2019 | 85 | 0.340 |
Why?
| Diet | 3 | 2008 | 564 | 0.330 |
Why?
| Hypoglycemic Agents | 1 | 2010 | 166 | 0.330 |
Why?
| Treatment Outcome | 16 | 2019 | 5138 | 0.330 |
Why?
| Infant Food | 1 | 2008 | 29 | 0.320 |
Why?
| Aorta | 3 | 2016 | 160 | 0.320 |
Why?
| Ketorolac Tromethamine | 1 | 2007 | 2 | 0.310 |
Why?
| Myocytes, Smooth Muscle | 2 | 2005 | 87 | 0.300 |
Why?
| Risk Factors | 9 | 2018 | 3619 | 0.300 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2007 | 39 | 0.300 |
Why?
| Thrombosis | 2 | 2017 | 249 | 0.290 |
Why?
| Catheterization, Peripheral | 2 | 2017 | 47 | 0.270 |
Why?
| Female | 23 | 2019 | 26329 | 0.270 |
Why?
| Postoperative Complications | 7 | 2019 | 1000 | 0.270 |
Why?
| Patient Discharge | 2 | 2019 | 322 | 0.270 |
Why?
| Pravastatin | 1 | 2006 | 18 | 0.270 |
Why?
| Hyperhomocysteinemia | 2 | 2011 | 29 | 0.260 |
Why?
| Antioxidants | 1 | 2007 | 248 | 0.260 |
Why?
| Arteries | 2 | 2017 | 94 | 0.260 |
Why?
| Aorta, Abdominal | 3 | 2019 | 41 | 0.250 |
Why?
| Renal Dialysis | 2 | 2003 | 169 | 0.250 |
Why?
| Ischemia | 4 | 2008 | 152 | 0.250 |
Why?
| Platelet Aggregation | 1 | 2005 | 71 | 0.240 |
Why?
| Smoke | 1 | 2004 | 18 | 0.240 |
Why?
| Blood Platelets | 2 | 2006 | 245 | 0.240 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 138 | 0.240 |
Why?
| Cell Division | 1 | 2005 | 292 | 0.240 |
Why?
| Humans | 29 | 2019 | 49827 | 0.240 |
Why?
| Folic Acid | 2 | 2003 | 135 | 0.240 |
Why?
| Hospitals, Veterans | 1 | 2003 | 110 | 0.220 |
Why?
| Endothelium, Vascular | 1 | 2005 | 254 | 0.220 |
Why?
| Stents | 4 | 2019 | 338 | 0.220 |
Why?
| Aged | 15 | 2019 | 9272 | 0.220 |
Why?
| Albumins | 1 | 2003 | 32 | 0.220 |
Why?
| Ultrasonic Therapy | 1 | 2003 | 32 | 0.220 |
Why?
| Oxidative Stress | 1 | 2007 | 768 | 0.220 |
Why?
| Arteriovenous Shunt, Surgical | 1 | 2003 | 29 | 0.210 |
Why?
| Fluorocarbons | 1 | 2003 | 45 | 0.210 |
Why?
| Middle Aged | 15 | 2017 | 11997 | 0.210 |
Why?
| Punctures | 6 | 2017 | 47 | 0.210 |
Why?
| Femoral Vein | 2 | 2015 | 40 | 0.210 |
Why?
| Age Factors | 4 | 2018 | 1090 | 0.210 |
Why?
| Arkansas | 6 | 2017 | 1967 | 0.210 |
Why?
| Collagen | 1 | 2003 | 206 | 0.200 |
Why?
| Contrast Media | 1 | 2003 | 183 | 0.200 |
Why?
| Fibrinolytic Agents | 2 | 2017 | 125 | 0.190 |
Why?
| Prosthesis-Related Infections | 2 | 2016 | 103 | 0.190 |
Why?
| Wounds, Nonpenetrating | 2 | 2016 | 82 | 0.190 |
Why?
| Length of Stay | 3 | 2019 | 623 | 0.190 |
Why?
| Angioplasty, Balloon | 2 | 2007 | 65 | 0.190 |
Why?
| Retrospective Studies | 13 | 2017 | 6117 | 0.190 |
Why?
| Blue Toe Syndrome | 1 | 2000 | 3 | 0.180 |
Why?
| Recurrence | 3 | 2017 | 651 | 0.180 |
Why?
| Models, Animal | 3 | 2006 | 233 | 0.180 |
Why?
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2004 | 57 | 0.180 |
Why?
| Angiography | 3 | 2017 | 126 | 0.170 |
Why?
| Vascular Patency | 6 | 2015 | 83 | 0.160 |
Why?
| Hospital Costs | 1 | 2019 | 73 | 0.160 |
Why?
| Cardiac Catheterization | 2 | 2001 | 196 | 0.160 |
Why?
| Clinical Competence | 2 | 2018 | 398 | 0.150 |
Why?
| Wound Infection | 2 | 2016 | 27 | 0.150 |
Why?
| Health Care Surveys | 1 | 2018 | 174 | 0.150 |
Why?
| Equipment Design | 5 | 2017 | 282 | 0.150 |
Why?
| Dietary Supplements | 1 | 2001 | 441 | 0.150 |
Why?
| Thrombolytic Therapy | 2 | 2017 | 111 | 0.150 |
Why?
| Dietary Sucrose | 2 | 2010 | 14 | 0.150 |
Why?
| Mechanical Thrombolysis | 1 | 2017 | 8 | 0.150 |
Why?
| Hospitals, Pediatric | 1 | 2018 | 239 | 0.140 |
Why?
| Postoperative Hemorrhage | 1 | 2017 | 52 | 0.140 |
Why?
| Behavior, Addictive | 1 | 2017 | 58 | 0.140 |
Why?
| Blood Loss, Surgical | 1 | 2017 | 73 | 0.140 |
Why?
| Mentors | 1 | 2017 | 55 | 0.140 |
Why?
| Immunohistochemistry | 3 | 2005 | 971 | 0.130 |
Why?
| Venous Thrombosis | 1 | 2017 | 91 | 0.130 |
Why?
| Thoracic Injuries | 1 | 2016 | 35 | 0.130 |
Why?
| Hypertension | 1 | 2001 | 532 | 0.130 |
Why?
| Collateral Circulation | 2 | 2008 | 39 | 0.130 |
Why?
| Attitude of Health Personnel | 1 | 2018 | 348 | 0.130 |
Why?
| Aortic Diseases | 1 | 2015 | 54 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2017 | 208 | 0.120 |
Why?
| Surgical Flaps | 1 | 2016 | 119 | 0.120 |
Why?
| Cystathionine beta-Synthase | 2 | 2004 | 17 | 0.120 |
Why?
| Insulin | 2 | 2010 | 457 | 0.120 |
Why?
| International Normalized Ratio | 1 | 2014 | 29 | 0.120 |
Why?
| Angioplasty | 2 | 2011 | 20 | 0.120 |
Why?
| Leg | 3 | 2007 | 122 | 0.120 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 488 | 0.120 |
Why?
| Tomography, X-Ray Computed | 3 | 2016 | 1159 | 0.120 |
Why?
| Blood Coagulation | 1 | 2014 | 57 | 0.120 |
Why?
| Dogs | 3 | 2003 | 182 | 0.110 |
Why?
| Acute Kidney Injury | 1 | 2017 | 283 | 0.110 |
Why?
| Reoperation | 4 | 2015 | 452 | 0.110 |
Why?
| Comorbidity | 3 | 2017 | 618 | 0.110 |
Why?
| Random Allocation | 2 | 2004 | 280 | 0.110 |
Why?
| Registries | 4 | 2019 | 518 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 2 | 2007 | 1374 | 0.110 |
Why?
| Regional Blood Flow | 2 | 2010 | 108 | 0.100 |
Why?
| Infusion Pumps, Implantable | 1 | 2011 | 13 | 0.100 |
Why?
| Jugular Veins | 1 | 2011 | 31 | 0.100 |
Why?
| Kaplan-Meier Estimate | 3 | 2019 | 469 | 0.100 |
Why?
| Estrogen Replacement Therapy | 1 | 2011 | 41 | 0.100 |
Why?
| Ovariectomy | 1 | 2011 | 119 | 0.100 |
Why?
| Anticoagulants | 1 | 2014 | 254 | 0.100 |
Why?
| Multivariate Analysis | 3 | 2017 | 585 | 0.090 |
Why?
| Odds Ratio | 3 | 2017 | 548 | 0.090 |
Why?
| Radial Artery | 1 | 2011 | 31 | 0.090 |
Why?
| Ultrasonography, Doppler, Pulsed | 1 | 2010 | 2 | 0.090 |
Why?
| Survival Rate | 3 | 2016 | 905 | 0.090 |
Why?
| Blood Flow Velocity | 1 | 2010 | 99 | 0.090 |
Why?
| Saphenous Vein | 1 | 2011 | 65 | 0.090 |
Why?
| Aged, 80 and over | 4 | 2019 | 3125 | 0.090 |
Why?
| Recovery of Function | 2 | 2017 | 189 | 0.090 |
Why?
| Hemorrhage | 2 | 2014 | 202 | 0.090 |
Why?
| Logistic Models | 3 | 2017 | 891 | 0.090 |
Why?
| Coronary Artery Bypass | 1 | 2011 | 120 | 0.090 |
Why?
| United States | 4 | 2019 | 4838 | 0.090 |
Why?
| Adult | 8 | 2017 | 13160 | 0.090 |
Why?
| Madagascar | 1 | 2008 | 2 | 0.080 |
Why?
| Follow-Up Studies | 4 | 2019 | 2179 | 0.080 |
Why?
| Celiac Artery | 1 | 2008 | 7 | 0.080 |
Why?
| Ligaments | 1 | 2008 | 12 | 0.080 |
Why?
| Popliteal Vein | 1 | 2008 | 13 | 0.080 |
Why?
| Angiography, Digital Subtraction | 1 | 2008 | 27 | 0.080 |
Why?
| Infant Nutritional Physiological Phenomena | 1 | 2008 | 55 | 0.080 |
Why?
| Eating | 1 | 2008 | 162 | 0.080 |
Why?
| Vasodilator Agents | 1 | 2008 | 97 | 0.080 |
Why?
| Malondialdehyde | 1 | 2007 | 51 | 0.080 |
Why?
| Endarterectomy | 1 | 2007 | 8 | 0.080 |
Why?
| Blood Glucose | 1 | 2010 | 432 | 0.080 |
Why?
| Platelet Activation | 1 | 2007 | 46 | 0.070 |
Why?
| Severity of Illness Index | 2 | 2007 | 942 | 0.070 |
Why?
| Graft Occlusion, Vascular | 2 | 2007 | 74 | 0.070 |
Why?
| Coronary Artery Disease | 1 | 2011 | 274 | 0.070 |
Why?
| Breast Feeding | 1 | 2008 | 184 | 0.070 |
Why?
| Abdominal Injuries | 1 | 2006 | 36 | 0.070 |
Why?
| Glutathione | 1 | 2007 | 295 | 0.070 |
Why?
| Limb Salvage | 2 | 2016 | 38 | 0.070 |
Why?
| Constriction | 2 | 2004 | 9 | 0.070 |
Why?
| Drug Combinations | 1 | 2006 | 123 | 0.070 |
Why?
| Dizocilpine Maleate | 1 | 2005 | 15 | 0.060 |
Why?
| Interleukin-1 | 1 | 2005 | 104 | 0.060 |
Why?
| Cholesterol | 1 | 2006 | 146 | 0.060 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2005 | 86 | 0.060 |
Why?
| Homocystine | 1 | 2004 | 8 | 0.060 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2005 | 50 | 0.060 |
Why?
| DNA, Complementary | 1 | 2005 | 135 | 0.060 |
Why?
| Cell Count | 1 | 2005 | 146 | 0.060 |
Why?
| Platelet Function Tests | 1 | 2004 | 17 | 0.060 |
Why?
| Lower Extremity | 1 | 2005 | 88 | 0.060 |
Why?
| Cell Culture Techniques | 1 | 2005 | 99 | 0.060 |
Why?
| C-Reactive Protein | 1 | 2006 | 142 | 0.060 |
Why?
| Aorta, Thoracic | 1 | 2005 | 92 | 0.060 |
Why?
| Cotinine | 1 | 2004 | 22 | 0.060 |
Why?
| Patient Selection | 2 | 2017 | 251 | 0.060 |
Why?
| Probability | 1 | 2004 | 164 | 0.060 |
Why?
| Constriction, Pathologic | 2 | 2008 | 94 | 0.060 |
Why?
| Cell Movement | 1 | 2005 | 247 | 0.060 |
Why?
| Reference Values | 1 | 2004 | 310 | 0.060 |
Why?
| RNA | 1 | 2005 | 170 | 0.060 |
Why?
| Biopsy, Needle | 1 | 2004 | 183 | 0.060 |
Why?
| Arginine | 1 | 2005 | 179 | 0.060 |
Why?
| Blotting, Western | 1 | 2005 | 602 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 595 | 0.060 |
Why?
| Cystathionine gamma-Lyase | 1 | 2003 | 4 | 0.060 |
Why?
| Platelet Adhesiveness | 1 | 2003 | 13 | 0.060 |
Why?
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 16 | 0.060 |
Why?
| Elastin | 1 | 2003 | 22 | 0.060 |
Why?
| Polytetrafluoroethylene | 1 | 2003 | 32 | 0.060 |
Why?
| Nitric Oxide | 1 | 2005 | 253 | 0.060 |
Why?
| Analysis of Variance | 1 | 2004 | 565 | 0.060 |
Why?
| Anastomosis, Surgical | 1 | 2003 | 68 | 0.060 |
Why?
| Myocardial Infarction | 2 | 2011 | 382 | 0.060 |
Why?
| Microspheres | 1 | 2003 | 25 | 0.060 |
Why?
| Dietary Carbohydrates | 1 | 2003 | 88 | 0.050 |
Why?
| Equipment Failure | 2 | 2017 | 62 | 0.050 |
Why?
| Extracellular Matrix | 1 | 2003 | 111 | 0.050 |
Why?
| Gene Expression | 1 | 2005 | 608 | 0.050 |
Why?
| Dietary Fats | 1 | 2003 | 133 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2004 | 854 | 0.050 |
Why?
| Feasibility Studies | 2 | 2017 | 374 | 0.050 |
Why?
| United States Department of Veterans Affairs | 1 | 2003 | 279 | 0.050 |
Why?
| RNA, Messenger | 1 | 2005 | 1105 | 0.050 |
Why?
| Cells, Cultured | 1 | 2005 | 1571 | 0.050 |
Why?
| Cell Proliferation | 1 | 2005 | 1007 | 0.050 |
Why?
| Models, Cardiovascular | 1 | 2001 | 21 | 0.050 |
Why?
| Rats, Inbred SHR | 1 | 2001 | 35 | 0.050 |
Why?
| Epigastric Arteries | 1 | 2000 | 2 | 0.050 |
Why?
| Groin | 2 | 2016 | 16 | 0.050 |
Why?
| Abdominal Muscles | 1 | 2000 | 14 | 0.050 |
Why?
| Staining and Labeling | 1 | 2001 | 97 | 0.050 |
Why?
| Pneumonia | 1 | 2001 | 117 | 0.050 |
Why?
| Actins | 1 | 2001 | 118 | 0.050 |
Why?
| Embolism | 1 | 2000 | 20 | 0.050 |
Why?
| Infant | 1 | 2008 | 3551 | 0.040 |
Why?
| Models, Biological | 1 | 2003 | 728 | 0.040 |
Why?
| Radiography, Interventional | 1 | 2000 | 60 | 0.040 |
Why?
| Survival Analysis | 1 | 2001 | 659 | 0.040 |
Why?
| Retreatment | 1 | 2019 | 58 | 0.040 |
Why?
| United States Food and Drug Administration | 1 | 1999 | 92 | 0.040 |
Why?
| Cost Savings | 1 | 2019 | 58 | 0.040 |
Why?
| Operative Time | 1 | 2019 | 75 | 0.040 |
Why?
| Stroke | 2 | 2017 | 492 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2014 | 904 | 0.040 |
Why?
| Cause of Death | 1 | 2019 | 145 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2019 | 273 | 0.040 |
Why?
| Prosthesis Design | 1 | 2019 | 236 | 0.040 |
Why?
| Postoperative Period | 1 | 1998 | 172 | 0.040 |
Why?
| Linear Models | 1 | 1998 | 281 | 0.040 |
Why?
| Risk Assessment | 2 | 2017 | 1262 | 0.040 |
Why?
| Young Adult | 2 | 2017 | 3936 | 0.040 |
Why?
| Critical Care | 1 | 2019 | 201 | 0.040 |
Why?
| Patient Readmission | 1 | 2019 | 222 | 0.040 |
Why?
| Blindness | 1 | 2017 | 31 | 0.040 |
Why?
| Social Networking | 1 | 2017 | 15 | 0.040 |
Why?
| Ischemic Attack, Transient | 1 | 2017 | 56 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2017 | 102 | 0.030 |
Why?
| Watchful Waiting | 1 | 2016 | 27 | 0.030 |
Why?
| Heart Failure | 1 | 2001 | 454 | 0.030 |
Why?
| Tertiary Care Centers | 1 | 2016 | 77 | 0.030 |
Why?
| Tissue and Organ Harvesting | 1 | 2015 | 24 | 0.030 |
Why?
| Chi-Square Distribution | 1 | 2016 | 282 | 0.030 |
Why?
| Treatment Failure | 1 | 2015 | 113 | 0.030 |
Why?
| Academic Medical Centers | 1 | 2015 | 132 | 0.030 |
Why?
| Sex Factors | 1 | 2017 | 693 | 0.030 |
Why?
| Trauma Centers | 1 | 2016 | 204 | 0.030 |
Why?
| Wound Healing | 1 | 2016 | 206 | 0.030 |
Why?
| Internet | 1 | 2017 | 261 | 0.030 |
Why?
| Vascular Access Devices | 1 | 2014 | 23 | 0.030 |
Why?
| Biomedical Research | 1 | 2017 | 231 | 0.030 |
Why?
| Curriculum | 1 | 2017 | 404 | 0.030 |
Why?
| Databases, Factual | 1 | 2017 | 664 | 0.030 |
Why?
| Ultrasonography, Interventional | 1 | 2014 | 135 | 0.030 |
Why?
| Prospective Studies | 1 | 2017 | 2344 | 0.020 |
Why?
| Adolescent | 2 | 2017 | 6340 | 0.020 |
Why?
| Myocardial Revascularization | 1 | 2011 | 13 | 0.020 |
Why?
| Coronary Angiography | 1 | 2011 | 336 | 0.020 |
Why?
| Injections, Intra-Arterial | 1 | 2008 | 13 | 0.020 |
Why?
| Mesenteric Artery, Superior | 1 | 2008 | 10 | 0.020 |
Why?
| Hypoxanthines | 1 | 1988 | 1 | 0.020 |
Why?
| Inosine | 1 | 1988 | 1 | 0.020 |
Why?
| Xanthines | 1 | 1988 | 8 | 0.020 |
Why?
| Renal Circulation | 1 | 1988 | 59 | 0.020 |
Why?
| Device Removal | 1 | 2008 | 85 | 0.020 |
Why?
| Syndrome | 1 | 2008 | 234 | 0.020 |
Why?
| Adenosine | 1 | 1988 | 69 | 0.020 |
Why?
| Alloys | 1 | 2007 | 9 | 0.020 |
Why?
| Image Enhancement | 1 | 2007 | 54 | 0.020 |
Why?
| Arteriovenous Fistula | 1 | 2006 | 21 | 0.020 |
Why?
| Aneurysm, False | 1 | 2006 | 44 | 0.020 |
Why?
| Catheterization | 1 | 2006 | 97 | 0.020 |
Why?
| Infusions, Intra-Arterial | 1 | 2005 | 16 | 0.020 |
Why?
| Blood Pressure | 1 | 1988 | 514 | 0.020 |
Why?
| Ultrasonography | 1 | 2006 | 436 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2006 | 448 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2006 | 1036 | 0.010 |
Why?
| Xanthine | 1 | 1988 | 2 | 0.000 |
Why?
| Phentolamine | 1 | 1988 | 7 | 0.000 |
Why?
| Hypoxanthine | 1 | 1988 | 4 | 0.000 |
Why?
| Receptors, Adrenergic, alpha | 1 | 1988 | 15 | 0.000 |
Why?
| Adrenergic alpha-Antagonists | 1 | 1988 | 27 | 0.000 |
Why?
| Adenosine Triphosphate | 1 | 1988 | 234 | 0.000 |
Why?
|
|
Moursi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|